

---

## BIOGRAPHICAL SKETCH

---

**Name:** Prof. Dr. rer. nat. Tobias Bald  
**Date of birth:** 31.05.1986  
**Position:** Tenure-Track W2-Profssor for Tumor-Immunobiology  
**Nationality:** German  
**Address:** Kiefernweg 36, 53127 Bonn, NRW, Germany  
**Email:** [Tobias.Bald@ukbonn.de](mailto:Tobias.Bald@ukbonn.de)  
**Phone:** +49-151-1788 9637  
**ORCID:** 0000-0003-0061-235X



### **Education and Training:**

Institution & Location	Degree	Date Completed	Field of study
University of Bonn, Germany	Diploma	10/2010	Molecular Biomedicine - Tumour Immunology -
University of Bonn, Germany	PhD (with highest honors, summa cum laude)	02/2015	Molecular Biomedicine - Tumour Immunology -

### **Employment and appointment history:**

2021-2025 **Tenure Track W2-Professor for Tumor-Immunobiology**, Institute for experimental Oncology, University Hospital Bonn, Bonn, Germany  
2020-present **Member of the Scientific Advisory Board** Carolina Zani Foundation, Brescia, Italy  
2019-present **Member of the Scientific Advisory Board** OncoMyx Therapeutics, Phoenix, USA  
2019-present **Scientific Advisor** for Axelia Oncology PTY, Melbourne, Australia  
2018-2020 **Junior Group Leader**, Oncology and Cellular Immunology, QIMR Berghofer Medical Research Institute, Brisbane, Australia  
2016-2018 **Post-Doc**, Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Brisbane, Australia headed by Prof. Mark J. Smyth  
2015-2016 **Post-Doc**, Laboratory for experimental Dermatology, University of Magdeburg, Magdeburg, Germany; Headed by Prof. Dr. med. Thomas Tüting  
2010-2015 **PhD-student**, Laboratory for experimental Dermatology, University of Bonn, Bonn, Germany; Supervisor Prof. Dr. med. Thomas Tüting and Prof. Sven Burgdorf  
2009-2010 **Diploma-Student**, Laboratory for experimental Dermatology, University of Bonn, Bonn, Germany; Supervisor Prof. Dr. med. Thomas Tüting

**Funding** Since 2016 I acquired over **~1.6 million EUR** in research funding

2020-2022 Melanoma Research Alliance (220.000 USD)  
2019-2020 Bristol-Myers-Squibb (850.000 AUD)  
2019-2020 EnaTherapeutics (350.000 AUD)  
2019-2020 QIMR Berghofer Proof of Concept Grant (99.478 AUD)  
2018-2019 QIMR Berghofer Seed Grant (49.940 AUD)  
2018-2021 NH&MRC Project Grant (453.638 AUD)  
2017-2018 QIMR Berghofer Seed Grant (40.000 AUD)  
2017-2021 NH&MRC early career Fellowship (426.396 AUD)  
2016-2018 EMBO long-term Fellowship (250.000 AUD)

## Intellectual Property

2019 Title of the Invention: "CELLS, COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE FUNCTION" currently submitted by Davies Collison Cave Pty Ltd decision pending.

## Top 5 publications

I have published a total of 39 peer reviewed articles in high impact journals (Nature, Nature Immunology, Cancer Cell, Cancer Discovery and Immunity) with a total of 2933 citations (*h*-index 22). A detailed list of publications is attached.

1. Braun M., ... Smyth MJ.\*, **Bald T.\*** (2020) CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells *Immunity*. 2020 Oct 13; 4:824-839. \* contributed equally **IF: 19.7 Citations: 7**
2. Glodde N\*, **Bald T\***, et al. (2017) Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. *Immunity*. 2017 Oct 17;47(4):789-802.e9 \* contributed equally **IF: 19.7 Citations: 118**
3. **Bald T**, et al. (2014) Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation. *Cancer Discovery*, 4:674-87. **IF: 24.4 Citations: 194**
4. **Bald T**, et al. (2014). Ultraviolet radiation-induced inflammation promotes angiogenesis and metastasis in melanoma. *Nature*. 507, 109-13. **IF: 40.1 Citations: 456**
5. Landsberg J\*, Kohlmeyer J\*, Renn M\*, **Bald T**, et al, (2012). Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. *Nature*. 490, 412-416. \* contributed equally **IF: 40.1 Citations: 434**

## Conference presentations (only invited)

- 2021 Cell and Experimental Biology conference
- 2021 Guest Symposium of Australian and New Zealand Society of Immunology (ASI) and German Society of Immunology (DGFI) at the 6th European Congress of Immunology
- 2021 4<sup>th</sup> Aegean Conference on Cytokines and Cancer
- 2019 Chair of the organizing committee for the 3<sup>rd</sup> Brisbane Immunotherapy Meeting
- 2018 Invited Speaker at the World Congress of Cancer of the Skin
- 2017 Invited Speaker at the Brisbane Immunology Group Meeting
- 2017 Invited Speaker at the 3<sup>rd</sup> Brisbane Cancer Conference
- 2017 Invited Speaker at the 44<sup>th</sup> Meeting of the Clinical Oncology Society of Australia
- 2014 Invited Speaker at the XXII International Pigment Cell Conference, Singapore
- 2014 Invited Speaker at the 42<sup>nd</sup> Annual Meeting of the ADF, Germany

## Individual honours, awards, prizes

- 2017 NHMRC ECF Award
- 2016 EMBO long-term Fellowship
- 2015 Egon-Macher Award of the ADF
- 2015 Best Publication in 2014 Bonner Forum Biomedicine (Bald et al. Nature 2014)
- 2014 Travel award of the society for melanoma research (SMR)
- 2014 Best Poster at the Bonner Forum Biomedicine
- 2014 Fluer Hiege Memorial award
- 2013 Best oral presentation Cluster Science Day
- 2013 Best Poster at the 6<sup>th</sup> International Investigative Dermatology Meeting
- 2013 Best Poster at the 40<sup>th</sup> ADF Meeting

### **Professional Memberships**

2017-present	Member of the Australasian Society for Immunology
2015-present	Member of the European Academy for Tumor Immunology
2012-present	Member of Society for Melanoma Research (SMR)
2012-present	Member of the German Society for Immunology (DGFI)
2012-present	Member of the European Society for Pigment Cell Research

### **Supervision and Mentoring**

I am currently supervising 1 Research Assistant, 1 PhD Student and 2 Post-Docs in my Laboratory at the University Hospital Bonn. Previously, I have mentored 4 B.Sc.; 3 M.Sc.; and 4 PhD.

### **Teaching**

2020-present	Lecturer; Medical Immunoscience and Infection (M.Sc. Program at the University Hospital Bonn)
2016-2019	Organisation of the seminar series “Cancer Biology” at the QIMR Berghofer Medical Research Institute
2012-2015	Lecturer; “Trends in Tumour immunology I + II” for Molecular Biomedicine students at the University of Bonn
2010-2015	Organisation and supervision of the practical course “Tumour immunology and mouse models for melanoma” for Molecular Biomedicine students at the University of Bonn

### **Peer review involvement**

Since 2021 I am deputy Editor for Clinical and Translational Immunology (IF 6.464).

I have reviewed manuscripts for Science (2), Nature Immunology (1), Nature Communications (4), Cancer Research (21), Cancer Immunology Research (8), Oncogene (4), Pigment cell melanoma Research (2) and Oncoimmunology (7) Clinical and Translational Immunology (36). I am also reviewing NH&MRC Project Grant applications and Grants for the Research Foundation Flanders (FWO, Belgium), German Research Council (DFG), the Deutsches Krebsforschungszentrum (DKFZ) and The Netherlands Organisation for Health Research and Development (ZonMw).

## **Peer-reviewed publications (in chronological order)**

1. [Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8<sup>+</sup> T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy.](#)  
Weulersse M, Asrir A, Pichler AC, Lemaitre L, Braun M, Carrié N, Joubert MV, Le Moine M, Do Souto L, Gaud G, Das I, Brauns E, Scarlata CM, Morandi E, Sundarrajan A, Cuisinier M, Buisson L, Maheo S, Kassem S, Agesta A, Pérès M, Verhoeyen E, Martinez A, Mazieres J, Dupré L, Gossye T, Pancaldi V, Guillerey C, Ayyoub M, Dejean AS, Saoudi A, Goriely S, Avet-Loiseau H, **Bald T**, Smyth MJ, Martinet L.  
*Immunity*. 2020 Oct 13;53(4):824-839.e10. PMID: 33053331
2. [CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8<sup>+</sup> T Cells.](#)  
Braun M, Aguilera AR, Sundarrajan A, Corvino D, Stannard K, Krumeich S, Das I, Lima LG, Meza Guzman LG, Li K, Li R, Salim N, Jorge MV, Ham S, Kelly G, Vari F, Lepletier A, Raghavendra A, Pearson S, Madore J, Jacquelin S, Effern M, Quine B, Koufariotis LT, Casey M, Nakamura K, Seo EY, Hölzel M, Geyer M, Kristiansen G, Taheri T, Ahern E, Hughes BGM, Wilmott JS, Long GV, Scolyer RA, Batstone MD, Landsberg J, Dietrich D, Pop OT, Flatz L, Dougall WC, Veillette A, Nicholson SE, Möller A, Johnston RJ, Martinet L, Smyth MJ, **Bald T**.  
*Immunity*. 2020 Oct 13;53(4):805-823.e15. PMID: 33053330
3. [The role of NK cell as central communicators in cancer immunity.](#)  
**Bald T**, Pedde AM, Corvino D, Böttcher JP.  
*Adv Immunol*. 2020;147:61-88. PMID: 32981635
4. [The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation.](#)  
Ng SS, De Labastida Rivera F, Yan J, Corvino D, Das I, Zhang P, Kuns R, Chauhan SB, Hou J, Li XY, Frame TCM, McEnroe BA, Moore E, Na J, Engel JA, Soon MSF, Singh B, Kueh AJ, Herold MJ, Montes de Oca M, Singh SS, Bunn PT, Aguilera AR, Casey M, Braun M, Ghazanfari N, Wani S, Wang Y, Amante FH, Edwards CL, Haque A, Dougall WC, Singh OP, Baxter AG, Teng MWL, Loukas A, Daly NL, Cloonan N, Degli-Esposti MA, Uzonna J, Heath WR, **Bald T**, Tey SK, Nakamura K, Hill GR, Kumar R, Sundar S, Smyth MJ, Engwerda CR.  
*Nat Immunol*. 2020 Oct;21(10):1205-1218. PMID: 32839608
5. [Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma.](#)  
Effern M, Glodde N, Braun M, Liebing J, Boll HN, Yong M, Bawden E, Hinze D, van den Boorn-Konijnenberg D, Daoud M, Aymans P, Landsberg J, Smyth MJ, Flatz L, Tüting T, **Bald T**, Gebhardt T, Hölzel M.  
*Immunity*. 2020 Sep 15;53(3):564-580.e9. PMID: 32750334
6. [The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies.](#)  
**Bald T**, Krummel MF, Smyth MJ, Barry KC.  
*Nat Immunol*. 2020 Aug;21(8):835-847. PMID: 32690952 Review.
7. [Cancer-killing, decoy-resistant interleukin-18.](#)  
Nakamura K, **Bald T**, Smyth MJ.  
*Immunol Cell Biol*. 2020 Jul;98(6):434-436. PMID: 32535941
8. [Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.](#)  
Lepletier A, Madore J, O'Donnell JS, Johnston RL, Li XY, McDonald E, Ahern E, Kuchel A, Eastgate M, Pearson SA, Mallardo D, Ascierto PA, Massi D, Merelli B, Mandala M, Wilmott JS, Menzies AM, Leduc C, Stagg J, Routy B, Long GV, Scolyer RA, **Bald T**, Waddell N, Dougall WC, Teng MWL, Smyth MJ.  
*Clin Cancer Res*. 2020 Jul 15;26(14):3671-3681. PMID: 32345648
9. [Innate Cancer Immunoediting.](#)

- Bald T, Smyth MJ.**  
J Invest Dermatol. 2020 Apr;140(4):745-747. PMID: 32200878
10. [Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis.](#)  
Kumar R, Bunn PT, Singh SS, Ng SS, Montes de Oca M, De Labastida Rivera F, Chauhan SB, Singh N, Faleiro RJ, Edwards CL, Frame TCM, Sheel M, Austin RJ, Lane SW, **Bald T**, Smyth MJ, Hill GR, Best SE, Haque A, Corvino D, Waddell N, Koufariotis L, Mukhopadhyay P, Rai M, Chakravarty J, Singh OP, Sacks D, Nysten S, Uzonna J, Sundar S, Engwerda CR. Cell Rep. 2020 Feb 25;30(8):2512-2525.e9. PMID: 32101732
  11. [Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.](#)  
Li XY, Moesta AK, Xiao C, Nakamura K, Casey M, Zhang H, Madore J, Lepletier A, Aguilera AR, Sundarrajan A, Jacobberger-Foissac C, Wong C, Dela Cruz T, Welch M, Lerner AG, Spatola BN, Soros VB, Corbin J, Anderson AC, Effern M, Hölzel M, Robson SC, Johnston RL, Waddell N, Smith C, **Bald T**, Geetha N, Beers C, Teng MWL, Smyth MJ. Cancer Discov. 2019 Dec;9(12):1754-1773. PMID: 31699796
  12. [Hide and seek: Plasticity of innate lymphoid cells in cancer.](#)  
**Bald T**, Wagner M, Gao Y, Koyasu S, Smyth MJ. Semin Immunol. 2019 Feb;41:101273. PMID: 30979591 Review.
  13. [TGFβ shuts the door on T cells.](#)  
**Bald T**, Smyth MJ. Br J Cancer. 2018 Jul;119(1):1-3. PMID: 29899392
  14. [CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.](#)  
Li XY, Das I, Lepletier A, Addala V, **Bald T**, Stannard K, Barkauskas D, Liu J, Aguilera AR, Takeda K, Braun M, Nakamura K, Jacquelin S, Lane SW, Teng MW, Dougall WC, Smyth MJ. J Clin Invest. 2018 Jun 1;128(6):2613-2625. PMID: 29757192
  15. [Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment.](#)  
Nakamura K, Kassem S, Cleynen A, Chrétien ML, Guillerey C, Putz EM, **Bald T**, Förster I, Vuckovic S, Hill GR, Masters SL, Chesi M, Bergsagel PL, Avet-Loiseau H, Martinet L, Smyth MJ. Cancer Cell. 2018 Apr 9;33(4):634-648.e5. PMID: 29551594
  16. [Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy.](#)  
Glodde N, **Bald T**, van den Boorn-Konijnenberg D, Nakamura K, O'Donnell JS, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, van der Sluis TC, Ruotsalainen JJ, Gaffal E, Landsberg J, Ludwig KU, Wilhelm C, Riek-Burchardt M, Müller AJ, Gebhardt C, Scolyer RA, Long GV, Janzen V, Teng MWL, Kastenmüller W, Mazzone M, Smyth MJ, Tüting T, Hölzel M. Immunity. 2017 Oct 17;47(4):789-802.e9. PMID: 29045907
  17. [Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.](#)  
Gao Y, Souza-Fonseca-Guimaraes F, **Bald T**, Ng SS, Young A, Ngiow SF, Rautela J, Straube J, Waddell N, Blake SJ, Yan J, Bartholin L, Lee JS, Vivier E, Takeda K, Messaoudene M, Zitvogel L, Teng MWL, Belz GT, Engwerda CR, Huntington ND, Nakamura K, Hölzel M, Smyth MJ. Nat Immunol. 2017 Sep;18(9):1004-1015. PMID: 28759001
  18. [MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy.](#)

- Reinhardt J, Landsberg J, Schmid-Burgk JL, Ramis BB, **Bald T**, Glodde N, Lopez-Ramos D, Young A, Ngiow SF, Nettersheim D, Schorle H, Quast T, Kolanus W, Schadendorf D, Long GV, Madore J, Scolyer RA, Ribas A, Smyth MJ, Tumeh PC, Tüting T, Hölzel M. *Cancer Res.* 2017 Sep 1;77(17):4697-4709. PMID: 28652246
19. [Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis.](#)  
Young A, Ngiow SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, Rautela J, **Bald T**, Barkauskas DS, Ahern E, Huntington ND, Schadendorf D, Long GV, Boyle GM, Hölzel M, Scolyer RA, Smyth MJ. *Cancer Res.* 2017 Sep 1;77(17):4684-4696. PMID: 28652244
  20. [Genome-wide in vivo screen identifies novel host regulators of metastatic colonization.](#)  
van der Weyden L, Arends MJ, Campbell AD, **Bald T**, Wardle-Jones H, Griggs N, Velasco-Herrera MD, Tüting T, Sansom OJ, Karp NA, Clare S, Gleeson D, Ryder E, Galli A, Tuck E, Cambridge EL, Voet T, Macaulay IC, Wong K; Sanger Mouse Genetics Project, Spiegel S, Speak AO, Adams DJ. *Nature.* 2017 Jan 12;541(7636):233-236. PMID: 28052056
  21. [Structural decoding of netrin-4 reveals a regulatory function towards mature basement membranes.](#)  
Reuten R, Patel TR, McDougall M, Rama N, Nikodemus D, Gibert B, Delcros JG, Prein C, Meier M, Metzger S, Zhou Z, Kaltenberg J, McKee KK, **Bald T**, Tüting T, Zigrino P, Djonov V, Bloch W, Clausen-Schaumann H, Poschl E, Yurchenco PD, Ehrbar M, Mehlen P, Stetefeld J, Koch M. *Nat Commun.* 2016 Nov 30;7:13515. PMID: 27901020
  22. [Basophils Promote Tumor Rejection via Chemotaxis and Infiltration of CD8+ T Cells.](#)  
Sektioğlu IM, Carretero R, Bulbuc N, **Bald T**, Tüting T, Rudensky AY, Hämmerling GJ. *Cancer Res.* 2017 Jan 15;77(2):291-302. PMID: 27879269
  23. [Phorbol ester-induced neutrophilic inflammatory responses selectively promote metastatic spread of melanoma in a TLR4-dependent manner.](#)  
**Bald T**, Landsberg J, Jansen P, Gaffal E, Tüting T. *Oncoimmunology.* 2015 Sep 1;5(2):e1078964. PMID: 27057457
  24. [Dickkopf-3 Contributes to the Regulation of Anti-Tumor Immune Responses by Mesenchymal Stem Cells.](#)  
Lu KH, Tounsi A, Shridhar N, Küblbeck G, Klevenz A, Prokosch S, **Bald T**, Tüting T, Arnold B. *Front Immunol.* 2015 Dec 24;6:645. PMID: 26734010
  25. [The experimental power of FR900359 to study Gq-regulated biological processes.](#)  
Schrage R, Schmitz AL, Gaffal E, Annala S, Kehraus S, Wenzel D, Büllsbach KM, **Bald T**, Inoue A, Shinjo Y, Galandrin S, Shridhar N, Hesse M, Grundmann M, Merten N, Charpentier TH, Martz M, Butcher AJ, Slodczyk T, Armando S, Efferm M, Namkung Y, Jenkins L, Horn V, Stöbel A, Dargatz H, Tietze D, Imhof D, Galés C, Drewke C, Müller CE, Hölzel M, Milligan G, Tobin AB, Gomeza J, Dohlman HG, Sondek J, Harden TK, Bouvier M, Laporte SA, Aoki J, Fleischmann BK, Mohr K, König GM, Tüting T, Kostenis E. *Nat Commun.* 2015 Dec 14;6:10156. PMID: 26658454
  26. [MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment.](#)  
Riesenberg S, Groetchen A, Siddaway R, **Bald T**, Reinhardt J, Smorra D, Kohlmeyer J, Renn M, Phung B, Aymans P, Schmidt T, Hornung V, Davidson I, Goding CR, Jönsson G, Landsberg J, Tüting T, Hölzel M. *Nat Commun.* 2015 Nov 4;6:8755. PMID: 26530832
  27. [A Preclinical Model of Malignant Peripheral Nerve Sheath Tumor-like Melanoma Is Characterized by Infiltrating Mast Cells.](#)

- Hölzel M, Landsberg J, Glodde N, **Bald T**, Rogava M, Riesenberg S, Becker A, Jönsson G, Tüting T.  
Cancer Res. 2016 Jan 15;76(2):251-63. PMID: 26511633
28. [Differential role of cannabinoids in the pathogenesis of skin cancer.](#)  
Glodde N, Jakobs M, **Bald T**, Tüting T, Gaffal E.  
Life Sci. 2015 Oct 1;138:35-40. PMID: 25921771
29. [Self-Antigen Presentation by Keratinocytes in the Inflamed Adult Skin Modulates T-Cell Auto-Reactivity.](#)  
Meister M, Tounsi A, Gaffal E, **Bald T**, Papatriantafyllou M, Ludwig J, Pougialis G, Bestvater F, Klotz L, Moldenhauer G, Tüting T, Hämmerling GJ, Arnold B, Oelert T.  
J Invest Dermatol. 2015 Aug;135(8):1996-2004. PMID: 25835957
30. [Cannabinoid 1 receptors in keratinocytes attenuate fluorescein isothiocyanate-induced mouse atopic-like dermatitis.](#)  
Gaffal E, Glodde N, Jakobs M, **Bald T**, Tüting T.  
Exp Dermatol. 2014 Jun;23(6):401-6. PMID: 24750433
31. [Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation.](#)  
**Bald T**, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P, Gaffal E, Steitz J, Tolba R, Kalinke U, Limmer A, Jönsson G, Hölzel M, Tüting T.  
Cancer Discov. 2014 Jun;4(6):674-87. PMID: 24589924
32. [Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma.](#)  
**Bald T**, Quast T, Landsberg J, Rogava M, Glodde N, Lopez-Ramos D, Kohlmeyer J, Riesenberg S, van den Boorn-Konijnenberg D, Hömig-Hölzel C, Reuten R, Schadow B, Weighardt H, Wenzel D, Helfrich I, Schadendorf D, Bloch W, Bianchi ME, Lugassy C, Barnhill RL, Koch M, Fleischmann BK, Förster I, Kastenmüller W, Kolanus W, Hölzel M, Gaffal E, Tüting T.  
Nature. 2014 Mar 6;507(7490):109-13. PMID: 24572365
33. [Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing.](#)  
Gehrke N, Mertens C, Zillinger T, Wenzel J, **Bald T**, Zahn S, Tüting T, Hartmann G, Barchet W.  
Immunity. 2013 Sep 19;39(3):482-95. PMID: 23993650
34. [Cannabinoid 1 receptors in keratinocytes modulate proinflammatory chemokine secretion and attenuate contact allergic inflammation.](#)  
Gaffal E, Cron M, Glodde N, **Bald T**, Kuner R, Zimmer A, Lutz B, Tüting T.  
J Immunol. 2013 May 15;190(10):4929-36. PMID: 23585676
35. [Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.](#)  
Landsberg J, Kohlmeyer J, Renn M, **Bald T**, Rogava M, Cron M, Fatho M, Lennerz V, Wölfel T, Hölzel M, Tüting T.  
Nature. 2012 Oct 18;490(7420):412-6. PMID: 23051752
36. [Peripheral lymphangiogenesis in mice depends on ectodermal connexin-26 \(Gjb2\).](#)  
Dicke N, Pielensticker N, Degen J, Hecker J, Tress O, **Bald T**, Gellhaus A, Winterhager E, Willecke K.  
J Cell Sci. 2011 Aug 15;124(Pt 16):2806-15. PMID: 21807945
37. [Neonatal UVB exposure accelerates melanoma growth and enhances distant metastases in Hgf-Cdk4\(R24C\) C57BL/6 mice.](#)  
Gaffal E, Landsberg J, **Bald T**, Sporleder A, Kohlmeyer J, Tüting T.  
Int J Cancer. 2011 Jul 15;129(2):285-94. PMID: 21207411
38. [Proteolytic processing of the serine protease matriptase-2: identification of the cleavage sites required for its autocatalytic release from the cell surface.](#)

Stirnberg M, Maurer E, Horstmeyer A, Kolp S, Frank S, **Bald T**, Arenz K, Janzer A, Prager K, Wunderlich P, Walter J, Gütschow M.

Biochem J. 2010 Aug 15;430(1):87-95. PMID: 20518742

39. [Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.](#)

Kohlmeyer J, Cron M, Landsberg J, **Bald T**, Renn M, Mikus S, Bondong S, Wikasari D, Gaffal E, Hartmann G, Tüting T.

Cancer Res. 2009 Aug 1;69(15):6265-74. PMID: 19622767

### **Peer-reviewed publications accepted for publication**

#### [BET Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection](#)

Mills RJ, Humphrey SJ, Fortuna PRJ, Quaipe-Ryan GA, Lor M, Ruraraju R, Rawle DJ, Le T, Zhao W, Lee L, Mackenzie-Kludas C, Mehdiabadi NR, Devilée L, Voges HK, Reynolds LT, Krumeich S, Mathieson E, Abu-Bonsrah D, Karavendzas K, Griffen B, Titmarsh D, Elliott DA, McMahon J, Suhrbier A, Subbarao K, Porrello ER, Smyth MJ, Engwerda CR, MacDonald KPA, **Bald T**, James DE, Hudson JE

Cell CELL-D-20-03794R3

#### [Myeloid cell type I IFN system promotes anti-tumor immunity over pro-tumoral inflammation in cancer T cell therapy](#)

Routsalainen J, Lopez Ramos D, Rogava M, Shridhar N, Glodde N, Gaffal E, Hölzel M, **Bald T**, Tüting T.

Clinical and Translational Immunology